fbpx
RESEARCH

PROLIGHT: PoC troponin testing ready for next step

Analys, Research

With proof-of-performance for its proprietary digital technique for detection of high-sensitive...

Read More

GRANGEX: Starting to fuel up: GRANGEX set for busy agenda in 2024 

Analys, Research

With the SEK 74 m (estimated 61m net) proceeds from the rights issue, we now look forward to the...

Read More

NANEXA: Focus on dual GLP-1 opportunities and the partner projects

Analys, Research

Apart from a write down of capitalized development related to the suspended projects NEX-18 and...

Read More

FREE2MOVE: Growth and improved focus on profitability catalysts for steep revaluation

Analys, Research

As expected, Free2Move reported solid growth in Q4, achieving a 59% growth rate for the full year....

Read More

CRUNCHFISH: Clearing the books in preparation for breakthrough in 2024

Analys, Research

In line with the already communicated ambition to divest its Gesture Interaction business,...

Read More

AGTIRA: Solid ending to 2023 before scaleup in 2024

Analys, Research

After several commercial contracts signed in 2023, Agtira ended the year with a strong cash...

Read More

AGTIRA: Video interview (SWE) with CEO Erik Jonuks about LIDL, the outlook and when AGTIRA will be profitable

Analys, Research

READ OUR MOST RECENT EQUITY RESEARCH REPORT  AGTIRA: Lidl deal solid stepping stone for Agtira...

Read More

PROLIGHT: Single molecule biomarker POC test upcoming

Analys, Research

Having already achieved proof-of-performance for its proprietary digital technique for detection of...

Read More
VIDEOS AND QUICKTAKES